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Abstract
Previously, our group engineered a plant-derived monoclonal antibody (MAb) (pHu-E16) that efficiently treated West Nile
virus (WNV) infection in mice. In this study, we developed several pHu-E16 variants to improve its efficacy. These variants
included a single-chain variable fragment (scFv) of pHu-E16 fused to the heavy chain (HC) constant domains (CH
1-3) of
human IgG (pHu-E16scFv-CH
1-3) and a tetravalent molecule (Tetra pHu-E16) assembled from pHu-E16scFv-CH
1-3 with a
second pHu-E16scFv fused to the light chain (LC) constant region. pHu-E16scFv-CH
1-3 and Tetra pHu-E16 were efficiently
expressed and assembled in plants. To assess the impact of differences in N-linked glycosylation on pHu-E16 variant
assembly and function, we expressed additional pHu-E16 variants with various combinations of HC and LC components. Our
study revealed that proper pairing of HC and LC was essential for the complete N-glycan processing of antibodies in both
plant and animal cells. Associated with their distinct N-glycoforms, pHu-E16, pHu-E16scFv-CH
1-3 and Tetra pHu-E16
exhibited differential binding to C1q and specific Fcc receptors (FccR). Notably, none of the plant-derived Hu-E16 variants
showed antibody-dependent enhancement (ADE) activity in CD32A+ human cells, suggesting the potential of plant-
produced antibodies to minimize the adverse effect of ADE. Importantly, all plant-derived MAb variants exhibited at least
equivalent in vitro neutralization and in vivo protection in mice compared to mammalian cell-produced Hu-E16. This study
demonstrates the capacity of plants to express and assemble a large, complex and functional IgG-like tetravalent mAb
variant and also provides insight into the relationship between MAb N-glycosylation, FccR and C1q binding, and ADE. These
new insights may allow the development of safer and cost effective MAb-based therapeutics for flaviviruses, and possibly
other pathogens.
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Introduction
The development and implementation of targeted monoclonal
antibody (MAb) therapy have provided new opportunities for
controlling a wide range of diseases. Although MAbs produced in
mammalian cell culture systems have achieved remarkable clinical
success, their high cost, long manufacturing time, and restricted
production capacity have limited the availability, utility and
potential of these drugs. Several of these challenges might be
overcome by using plant expression systems, because they offer
scalable production of MAbs at low cost with a low risk of
introducing adventitious human or animal pathogens [1–3].
Functional antibody production requires a eukaryotic host cell
that can assemble four antibody polypeptides into a heterote-
tramer and perform complex N-linked glycosylation. Despite this
complexity, a MAb was successfully expressed in tobacco plants
only three years after the first plant-made biologic [4]. Since then,
a variety of MAbs and their derivatives, such as IgG, IgA, single-
chain variable fragments (scFv), and diabodies have been
produced in plants [3]. The largest reported MAb-based molecule
produced in plants is a recombinant immune complex (RIC) [5].
The ability of plants to express and assemble larger or more
complex MAb-derived molecules such as tetravalent MAbs or
bifunctional MAbs has not been described.
N-linked glycosylation of proteins occurs as a series of post-
translational modification steps in host cells and depends on the
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proper folding of the target protein and its transport to the
appropriate endomembrane compartments [6]. As such, MAb
variants with significant polypeptide structural differences from the
native molecule also may have appreciable differences in glycan
structures. Structural differences also may impact the pharmaco-
kinetics, antigen binding, stability, effector functions, immunoge-
nicity, and efficacy of a MAb and its derivatives.
West Nile virus (WNV) is a neurotropic virus that infects the
central nervous system (CNS) of human and animals. Historically,
WNV was an Old World disease found mostly in the Eastern
Europe, Africa, and the Middle East. However, in 1999, WNV
entered the Western hemisphere and subsequently spread across
the United States (US), Canada, the Caribbean region and Latin
America [7] with outbreaks occurring on an annual basis. The
elderly and immunocompromised are the most vulnerable for
developing severe neurological disease, long-term morbidity, and
death [8], although genetic factors also are associated with an
increase risk of disease [9,10]. Currently, there is no vaccine or
therapeutic approved for human use. The global threat of WNV
epidemics and the lack of treatment warrant the development of
antiviral therapeutics and production platforms that can bring
products to market at low cost. We previously reported a plant-
derived, humanized murine MAb (pHu-E16) that binds to an
epitope on domain III (DIII) of WNV envelope (E) protein, as a
post-exposure therapeutic candidate for WNV [11]. We demon-
strated that pHu-E16 was produced at high levels and assembled
efficiently in both Nicotiana benthamiana and lettuce plants [11,12].
pHu-E16 retained antigen binding specificity, neutralized WNV
infection, and protected mice from lethal infection equivalently
compared to the mammalian cell-produced Hu-E16 (mHu-E16)
[11]. Because WNV is a neurotropic virus, peripheral delivery of
pHu-E16, however, likely will have a limited window of efficacy
due to its inability to cross the blood brain barrier (BBB) efficiently
and accumulate in the brain at concentrations sufficient for
neutralization. Thus, it would be desirable to develop pHu-E16
variants, such as bifunctional MAbs, that can cross the BBB while
retaining targeted therapeutic activity.
To test the ability of plants in producing such complex MAb
variants, here we expressed several pHu-E16 derivatives including
a pHu-E16scFv fused to the heavy chain (HC) constant domains
(CH
1-3) of human IgG (pHu-E16scFv-CH
1-3) and a large tetrava-
lent molecule (Tetra pHu-E16) assembled from pHu-E16scFv-
CH
1-3 with another pHu-E16scFv fused to the light chain (LC)
constant region (CL) (pHu-E16scFv-CL). We demonstrated that
plants can express and assemble these pHu-E16 variants
efficiently. These pHu-E16 variants also showed at least equivalent
protection as the parent pHu-E16 or mHu-E16 against a lethal
WNV challenge in a mouse model. Our results also revealed
differences in N-linked glycosylation pattern between different
MAb variants, and demonstrated that the proper pairing of HC
and LC was essential for the complete N-glycan processing of
antibodies in both plant and animal cells. We also found that pHu-
E16, pHu-E16scFv-CH
1-3 and Tetra pHu-E16 exhibited differen-
tial binding to specific Fcc receptors (FccRs) and C1q, the
complement opsonin that activates the classical complement
pathway. In human K562 cells, none of the plant-derived Hu-
E16 variants showed significant antibody-dependent enhancement
(ADE) activity, a phenomenon that is an impediment for
developing MAb-based therapeutics against flaviviruses, such as
the related Dengue virus. Overall, this study demonstrates the
capacity of a plant to assemble a large and complex IgG-like
tetravalent MAb, which offers a step forward toward the
development of bifunctional MAbs in plants.
Results
Expression and assembly of pHu-E16 scFv-CH
1-3 in N.
benthamiana
An important prerequisite for the generation of bifunctional
Hu-E16 MAb is the correct assembly of its functional component:
pHu-E16scFv-CH
1-3. The DNA sequence of the variable region of
HC (VH) and LC (VL) of pHu-E16 [11] was fused together first to
generate pHu-E16scFv, and then fused to the coding sequence of
the CH
1-3 of human IgG1 (Fig 1A). The resulting coding sequence
of pHu-E16scFv-CH
1-3 was cloned into a MagnICON-based plant
expression vector [13], and transformed into Agrobacterium
tumefaciens. A. tumefaciens strains containing the pHu-E16scFv-
CH
1-3 construct were co-delivered into N. benthamiana leaves along
with the promoter module and an integrase construct through
agroinfiltration [14,15]. Western blot analysis after reducing or
non-reducing gel electrophoresis confirmed that pHu-E16scFv-
CH
1-3 was produced in leaves with the expected molecular weight
(Fig 1B, Lane 5), and that it assembled into a dimer (Fig 1D,
Lane 7). ELISA results also indicated that pHu-E16scFv-CH1-3
reached the highest level of accumulation 9 days post infiltration
(dpi) with A. tumefaciens, with an average accumulation of 0.8 mg/g
leaf fresh weight (LFW) (Fig 2). This level is similar to that
previously reported for the parent pHu-E16 MAb, and is among
the highest expression levels for MAbs in plants ever described
[3,11,16].
pHu-E16 scFv-CH
1-3 exhibited altered N-linked
glycosylation pattern
A typical feature of IgG antibodies is a conserved N-linked
glycosylation site at position Asn297 in the CH
2 domain; it is well
documented that the pattern and extent of N-linked glycosylation
affects the stability and function of an antibody [17]. Accordingly,
we next examined the N-glycoforms of pHu-E16scFv-CH
1-3 by
liquid-chromatography-electrospray ionization-mass spectrometry
(LC-ESI-MS) to assess whether the extent of N-linked glycosyla-
tion was similar to that of the parent pHu-E16. pHu-E16 exhibited
the expected complex-type N-glycans (GnGnXF, Table 1) that
are typical for plant-produced IgGs [18]. However, pHu-E16scFv-
CH
1-3 displayed oligomannosidic structures, predominantly Man8
and Man9 (Table 1). The predominantly endoplasmic reticulum
(ER)-type N-glycans of pHu-E16scFv-CH
1-3 were unexpected, as
this molecule was targeted for secretion and not tagged with an
ER-retention signal KDEL. To investigate if this is a phenomenon
specific to plant cells, we also compared the N-glycan profiles of
the same Hu-E16 variants produced in mammalian cells (mHu-
E16 and mHu-E16scFv-CH
1-3). We observed a substantial amount
of oligomannosidic glycans (oligoman, mostly M5 and M7) in
mHu-E16scFv-CH
1-3 in addition to the predominant complex-type
glycans (GnGnF6 and AGnF6), whereas no such glycans were
observed in mHu-E16 (Table 1). This result suggests that the
unusual N-linked glycosylation pattern of scFv-CH
1-3 is not unique
to plants but also is shared by mammalian cells, even though the
percentage and the particular species of oligomannosidic glycans
differ between cells from the two species.
Expression and N-linked glycosylation of a tetravalent
pHu-E16 and other pHu-E16 variants
The success of pHu-E16 scFv-CH
1-3 expression and assembly in
plants indicates the feasibility of developing an IgG-like tetravalent
MAb variant. Such a form could provide four WNV antigen-
binding sites or enable development of bifunctional MAbs that
offer divalent binding to two different antigens. For example,
Novel Therapeutics against West Nile Virus
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bifunctional MAbs could be engineered to bind a BBB receptor as
its second antigen to enhance transport into the brain and extend
the window of treatment for neuroinvasive WNV infection. To
understand the basis of the difference in N-linked glycans between
pHu-E16scFv-CH
1-3 and its parent pHu-E16 and develop a
potentially more effective WNV therapeutic, we engineered and
expressed three additional pHu-E16 variants with various
combinations of HC and LC components. First, pHu-E16scFv
was fused to the plant-codon optimized CL (pHu-E16scFv-CL).
Three pHu-E16 variants were then produced in N. benthamiana
plants by the co-expression of the following Hu-E16 construct
combinations: scFv-CH1-3/LC, HC/scFv-CL, and scFv-CH
1-3/
scFv-CL (Fig 1A). Western blot analysis after reducing gel
electrophoresis confirmed that each component of the variants
was produced in plants with the expected molecular weight
(Fig 1B and C, Lanes 2–4). These protein bands were specific to
the infiltrated molecular constructs and were not detected in
samples from negative control plant leaves (Fig 1B and C, Lane
6). Moreover, western blotting after non-reducing gel electropho-
resis revealed that the two polypeptides in each combination
assembled into an IgG-like heterotetramer (Fig 1D, Lanes 2–4
and Fig 1A). The successful expression and assembly of pHu-
E16scFv-CH
1-3 with pHu-E16scFv-CL to form a tetravalent
molecule (Tetra pHu-E16, Fig 1B-D, Lane 3, and Fig 1A) in
plants is noteworthy, as the assembly of such large and complex
MAb variants has not been reported previously. Yield analysis by
ELISA established that Tetra pHu-E16 and other variants reached
the highest level of production at 9 dpi. Nonetheless, the
expression level varied between the three pHu-E16 variants, with
HC/scFv-CL’s comparable to that of the parent pHu-E16 and
pHu-E16scFv-CH
1-3 (690 mg/g LFW), scFv-CH1-3/LC’s (430 mg/
g LFW), and Tetra pHu-E16 (240 mg/g LFW) produced at slightly
lower levels (Fig 2).
In addition to developing a tetravalent pHu-E16 as a possible
novel WNV therapeutic molecule, the expression of the three
pHu-E16 variants also allowed us to study the cause of the
unexpected N-linked glycosylation of pHu-E16scFv-CH
1-3, specif-
ically to address whether LC or the proper pairing of HC and LC
affected N-linked glycosylation of MAb and its variants. Co-
expression of LC of pHu-E16 increased the percentage of
complex-type glycans in pHu-E16scFv-CH
1-3 (Table 1). In Tetra
pHu-E16, the co-expression and pairing of scFv-CH
1-3/scFv-CL
Figure 1. Western blot analysis of pHu-E16 variants. A. Designs of Hu-E16 variants in this study. B–D. Western blot analysis. Hu-E16 variants
were extracted from N. benthamiana leaves, separated on SDS-PAGE gels under reducing (B and C) or non-reducing (D) conditions, and blotted onto
PVDF membranes. The membranes were incubated with a goat anti-human gamma chain antibody or a goat anti-human kappa chain antibody to
detect heavy chain (B and Lane 7 of D) or light chain (C and Lanes 1–6 of D). Lane 1, pHu-E16 as a reference standard; lane 2, Protein sample
extracted from leaves co-infiltrated with pHu-E16 HC and pHu-E16scFv-CL constructs; lane 3, Sample from leaves co-infiltrated with pHu-E16scFv-CH
1-3
and pHu-E16scFv-CL; lane 4, Sample from leaves co-infiltrated with pHu-E16scFv-CH
1-3 and pHu-E16 LC; lanes 5 and 7, Sample from leaves infiltrated with
pHu-E16scFv-CH
1-3; lane 6, Sample from un-infiltrated leaves. HC: heavy chain, scFv: single-chain variable fragment; CH
1-3: the constant region domains 1
to 3 of HC; LC: light chain; CL: Constant region of LC; VL: variable region of LC; VH: variable region of HC.
doi:10.1371/journal.pone.0093541.g001
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also increased the amount of complex-type N-glycans (Table 1),
albeit not to the same level as in the scFv-CH
1-3/LC combination.
In contrast, pairing of the HC of pHu-E16 with scFv-CL yielded a
predominantly complex-type N-linked glycosylation pattern,
similar to that of the parent pHu-E16 (Table 1). These results
indicated the importance of LC pairing with HC for the complete
processing of N-linked glycans on antibodies.
Purification of pHu-E16 variants from N. benthamiana
leaves
For Tetra pHu-E16 and other variants to be feasible therapeutic
candidates for WNV, an efficient extraction and purification
process must be developed. We applied a scalable extraction and
purification process previously developed for pHu-E16 to the
purification of these variants [11]. Analysis of processing samples
with gel electrophoresis indicate that in spite of their structural
complexity, Tetra pHu-E16, pHu-E16scFv-CH
1-3, and other
variants were readily extracted from plant tissue and enriched to
.90% purity by a combination of ammonium sulfate precipitation
and protein A chromatography (Fig 3). These purified pHu-E16
variants were used for further functional studies.
pHu-E16 variants show differential binding to human Fcc
receptors and C1q and reduced antibody-dependent
enhancement activity
N-linked glycosylation in the Fc region of an antibody affects
binding to FccRs and C1q [17]. Accordingly, we investigated the
binding of pHu-E16scFv-CH
1-3 and Tetra pHu-E16 to C1q and
different human FccRs including CD16A-V158, CD16A-F158,
CD32A-R131, CD32A-H131, CD32B, and CD64 by surface
plasmon resonance (SPR) analysis using pHu-E16 and mHu-E16
as references. Compared to mHu-E16, pHu-E16 showed reduced
binding to all FccRs and C1q (Fig 4A). pHu-E16scFv-CH
1-3
showed slightly enhanced binding to CD64 and the low-affinity
(F158) isoform of CD16A, maintained similar binding to the high-
affinity (V158) CD16A isoform, and had reduced binding to
CD32A and B (Fig 4A). Tetra pHu-E16 showed a similar binding
profile of FccRs and C1q as pHu-E16scFv-CH1-3, except with T
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Figure 2. Time course of pHu-E16 expression in N. benthamiana
plants. Total proteins from leaves infiltrated or co-infiltrated with pHu-
E16scFv-CH
1-3, pHu-E16 HC/pHu-E16scFv-CL, pHu-E16scFv-CH
1-3/pHu-
E16scFv-CL (Tetra pHu-E16), or pHu-E16scFv-CH
1-3/pHu-E16 LC were
extracted on days 5 -10 post infiltration and analyzed by an ELISA that
detects the assembled form of pHu-E16 MAb variants, Mean 6 SD of
samples from three independent infiltrations are presented.
doi:10.1371/journal.pone.0093541.g002
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reduced binding to CD64 and the high affinity isoform (V158) of
CD16A (Fig 4A).
The interaction between Fc moieties and FccRs or C1q also
regulates antibody-dependent enhancement of infection (ADE), an
in vitro phenomenon that relevant to disease pathogenesis of some
flaviviruses [19-21]. As such, we investigated if plant-produced
Hu-E16 variants would have a unique ADE profile in vitro
compared to that of mHu-E16. As seen previously [22], mHu-
E16, which has a native Fc moiety including a key N-linked glycan
at position 297, efficiently promoted ADE in K562 cells that
express the human FccR CD32A (Fig 4B). In comparison, all
pHu-E16 variants tested did not display ADE activity in human
K562 cells, indicating the potential of plants to produce antibodies
or antibody-like molecules that minimize ADE.
Antigen binding and neutralization activity of pHu-E16
variants
We also assessed the relative binding and function of pHu-E16
variants in several assays. The binding of pHu-E16 variants to
WNV E DIII was determined by ELISA in which DIII was coated
on microtiter plates [11]. E16scFv-CH
1-3, Tetra pHu-E16 and
other pHu-E16 variants bound in a similar manner to DIII as
pHu-E16 (Fig 5A). Recognition of pHu-E16 variants for DIII was
corroborated in a binding assay with yeast that displayed DIII on
their surface. Flow cytometric analysis showed that the percentage
of positive yeast and the mean fluorescence intensity of binding by
saturating concentrations of pHu-E16scFv-CH
1-3 and mHu-E16
were similar (Fig 5B). Analogous results were obtained for Tetra
pHu-E16 and other variants (data not shown). The binding of
these variants to WNV E DIII was quantitated by a SPR assay
with the antibody captured on the chip and the recombinant
monomeric DIII flowed over in solution; as expected, E16scFv-
CH
1-3 and Tetra pHu-E16 had similar monovalent binding affinity
and kinetics (10 to 25 nM) for WNV E protein and DIII compared
to its parent mHu-E16 (data not shown). These results confirm
that E16scFv-CH
1-3 and Tetra pHu-E16 retained antigen-binding
activity and were comparable to pHu-E16 and mHu-E16.
To evaluate the neutralization potential of pHu-E16 variants,
we used a focus reduction neutralization assay that measures
antibody inhibition of WNV infection [12,23]. pHu-E16scFv-CH
1-3
and Tetra pHu-E16 neutralized WNV infection comparably to
mHu-E16 and pHu-E16 (Fig 6, EC50: mHu-E16=3.6 ng/ml,
pHu-E16=3.7 ng/ml, pHu-E16scFv-CH
1-3= 5.2 ng/ml, Tetra
pHu-E16=3.0 ng/ml, respectively). Thus, E16scFv-CH
1-3 and
Tetra pHu-E16 retained potent neutralizing activity against
infectious WNV.
pHu-E16 scFv-CH
1-3 and Tetra pHu-E16 have potent
prophylactic and therapeutic potential
Prophylaxis and therapeutic studies were performed to evaluate
the activity of pHu-E16 variants in vivo. Pre-treatment studies were
performed in 5 week-old wild type C57BL/6 mice (n$10, per
group) to compare the concentrations of pHu-E16scFv-CH
1-3 and
mHu-E16 that prevent WNV infection. Mice were inoculated with
102 PFU of WNV (New York 2000 strain), which causes a baseline
mortality of 80 to 90% in this model [24]. Increasing amounts (1
to 100 ng) of pHu-E16scFv-CH
1-3 or 100 ng of mHu-E16 were
administered as a single dose on the day of infection. Result
showed that 80% of mice were protected from lethal infection
when 100 ng of pHu-E16scFv-CH
1-3 was administered (P,0.05),
whereas the same dose of mHu-E16 protected 60% of mice
(Fig 7A). A single injection of as low as 10 ng of pHu-E16scFv-
CH
1-3 also prevented mortality (Fig 7A).
Post-exposure therapeutic treatments were performed by
passively administering a single dose of pHu-E16scFv-CH
1-3 or
Tetra pHu-E16 after subcutaneous inoculation of 102 PFU of
WNV. Since WNV spreads to the brain in mice by day 4 after
infection [25], we investigated the efficacy of pHu-E16 variants at
this time point. Initially, a 500 mg dose was used as a direct
comparison to our prior published results [11,25]; similar levels of
protection were observed between mHu-E16 and pHu-E16scFv-
CH
1-3 (data not shown). To define a lower limit of protection, we
used a dose of 50 mg (Fig 7B). Notably, 70% of mice were
protected from lethal infection when 50 mg of pHu-E16scFv-CH
1-3
was given 4 days after WNV inoculation, similar to that observed
with mHu-E16 performed in parallel (Fig 7B, P.0.6). A single
administration of 50 mg of Tetra pHu-E16 protected up to 90% of
mice from lethal infection, compared with an 80% survival rated
achieved by mHu-E16 (Fig 7B). Overall, pHu-E16 scFv-CH
1-3
and Tetra pHu-E16 had at least equivalent prophylactic and
therapeutic efficacy in mice compared to mHu-E16.
Discussion
MAb expression initially was attempted in stable transgenic
plants [4]. It suffered from low-yield, long lead time to generate
and select transgenic plants, and unstable seed banks largely due to
the randomness of transgene integration in the plant genome
(position effect), the lack of control in transgene copy number, and
the shortage of strong promoters to drive transgene expression [3].
This greatly undermined the cost-saving potential of the plant
expression systems. The development of transient expression
systems based on deconstructed virus vectors has increased the
speed and yield of MAb production in plants [13,26–28]. For
example, with the MagnICON and geminiviral vectors, MAbs can
be obtained within 10 days of vector infiltration into N. benthamiana
and lettuce plants with yields up to 1 mg MAb/g LFW [11,12,29–
31]. Although MAb derivatives, such as scFv, diabodies, and RIC
have been produced in plants [3,5,32], the ability of plants to
Figure 3. Purification of pHu-E16 variants from N. benthami-
ana leaves. Leaf proteins were extracted on day 9 after agroinfiltra-
tion. pHu-E16 variants were purified and analyzed on a 4-20% gradient
SDS-PAGE gel under reducing condition and visualized with Coomassie
stain. Lane 1, pHu-E16 as a reference standard; lane 2, pHu-E16 HC/pHu-
E16scFv-CL; lane 3, Tetra pHu-E16; lane 4, pHu-E16scFv-CH
1-3/pHu-E16
LC; lanes 5, pHu-E16scFv-CH
1-3. Ten mg of purified protein was loaded in
each lane of the gel. One representative of several independent
experiments is shown.
doi:10.1371/journal.pone.0093541.g003
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express and assemble larger or more complex MAb-derived
molecules such as IgG-like tetravalent MAbs or bifunctional MAbs
has not been reported.
Here, we investigated the feasibility of plant cells for producing
such an IgG-like tetravalent MAb against WNV based on MAb
Hu-E16. Our results showed that two Hu-E16scFvs each
genetically fused to the CH
1-3 and CL fragment of IgG can be
produced efficiently in N. benthamiana leaves. The Hu-E16scFv-
CH
1-3 and Hu-E16scFv-CL efficiently assembled into an IgG-like
molecule. Our study also demonstrated that the tetravalent pHu-
E16 retained antigen-binding and neutralization activity in vitro.
Most importantly, a single dose of Tetra-pHu-E16 protected mice
at least equivalently as mHu-E16 against a lethal WNV infection
several days after exposure. To our knowledge, this is the first
example in a plant of expression and assembly of a large and
complex IgG-like tetravalent functional molecule, although a
structurally unrelated secretory IgA (sIgA) molecule assembled
from polypeptides of four gene products was produced in stable
transgenic plants [4]. Tetra pHu-E16 was expressed rapidly in N.
benthamiana leaves and reached its highest level of accumulation 9
days after leaf infiltration. While its expression level is slightly
lower than that of pHu-E16, this level is within the range feasible
for commercial production [33], and likely can be increased by
further genetic optimization [3]. Tetra-pHu-E16 and other
variants were recovered efficiently to high (.90%) purity with a
two-step purification process. In addition to plant host proteins,
this process also effectively removed other contaminants including
endotoxin, with its levels ranging from 5.2 to 8.6 EU/ml in the
purified product (Q. Chen, unpublished data). The rapid
accumulation and assembly of Tetra pHu-16 and the availability
of a scalable and current Good Manufacturing Practice (cGMP)
Figure 4. FccR and C1q binding and antibody-dependent enhancement of pHu-E16 variants. A. SPR analysis of FccR and C1q binding.
FccRs including CD16A (CD16V158, CD16F158), CD32A (CD32A-R131 and CD32A-H131 fused to an aglycosylated Fc region of IgG2 (CD32A-R131-G2agl
and CD32A-H131-G2agl)), CD32B (CD32B fused to an aglycosylated Fc region of IgG2 (CD32B-G2agl)) and CD64, and C1q were injected at the same
concentration over the surfaces with Hu-E16 variants captured on immobilized WNV E protein. Buffer injection was subtracted as blank and responses
were normalized to same level of captured antibodies. B. ADE of WNV infection with antibody variants. Serial dilutions of Hu-E16 variants were mixed
with WNV RVP and added to CD32A-expressing K562 cells. Forty-eight hours later, cells were analyzed by flow cytometry for GFP expression.
doi:10.1371/journal.pone.0093541.g004
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compliant purification scheme suggest the viability of such
molecules as a platform for novel therapeutic candidates.
Another long-term goal of this research is to increase the
efficacy of Hu-E16 MAb as a proof-of-principle for antibody
treatment of viral infections in the CNS. Even though mHu-E16
[11,25], pHu-E16 [11,25], pHu-E16scFv-CH
1-3, and Tetra pHu-
E16 showed excellent efficacy, their window of clinical treatment
will be limited via peripheral delivery systems. These current
MAb-based molecules cannot accumulate to high levels in the
brain unless there is widespread inflammation and breakdown of
the BBB. Thus, it would be desirable to develop pHu-E16 variants
that can cross the BBB more efficiently. One possible strategy is to
develop IgG-like bifunctional MAbs that have a similar structure
as the Tetra pHu-E16, but are assembled from scFvs that bind to
two disparate antigens. For example, one of the two scFvs could
bind to a specific receptor (e.g., insulin receptor [34]) on BBB to
facilitate its transport into the brain, and the other scFv would
retain its binding to and neutralization of WNV in the brain. The
successful production and assembly of Tetra pHu-E16 and the
demonstration of its therapeutic activity bring us closer to
developing such Hu-E16 bifunctional MAbs to prolong the
window of its efficacy.
The N-linked glycosylation of MAbs affects its stability, FccR
and C1q binding, pharmacokinetics, effector function and efficacy
[17]. N-linked glycosylation occurs as a series of post-translational
modification steps initiated in the ER and processed through
different compartments of the Golgi complex of the host cell.
Altering the structure of a protein or its folding may affect glycan
modification and the corresponding cellular localization [35,36].
However, the impact of structural variations in the native IgG on
N-linked glycosylation has not been studied extensively. Here, we
first examined the difference in the N-linked glycans of pHu-E16
IgG and its pHu-E16scFv-CH
1-3 variant. Our results revealed that
their N-linked glycan profiles were different from one another.
pHu-E16 exhibited the expected complex-type N-linked glycans
[18], confirming it was fully processed through the endomembrane
system and secreted into the apoplast as designed. In contrast,
pHu-E16scFv-CH
1-3 predominantly displayed Man8 and Man9-
types of oligomannosidic structures, which indicates incomplete
glycan processing and suggests its aberrant localization in ER or
ER-derived vesicles. A similar observation in glycoforms and
aberrant subcellular deposition was reported for Arabidopsis
(Arabidopsis thaliana) seed-derived 2G12scFV-Fc, a MAb variant
recognizing Human immunodeficiency virus (HIV), and to a lesser
extend, for HA78scFv-Fc, an anti-hepatitis A virus MAb also
produced in Arabidopsis seed [35]. However, in the same study,
leaf-derived HA78scFv-Fc displayed the expected complex-type
N-glycans, whereas leaf-produced 2G12scFv-Fc exhibited the ER-
typical oligomannosidic glycans and was functionally inactive [35].
These observations suggest that beside the polypeptide component
of scFv-Fcs, the type of plant tissue (e.g. seed vs. leaf) and plant
species also may impact the N-linked glycosylation status of scFv-
Fc variants. It should be noted that the structures of 2G12scFv-Fc
and HA78scFv-Fc are different from pHu-E16scFv-CH
1-3, as their
scFvs were fused to the Fc fragment (hinge-CH
2-3) of IgG and lack
the HC constant region 1 domain (CH
1). To investigate if this was
Figure 5. Antigen binding of pHu-E16 variants to DIII of WNV E. A. ELISA analysis. Serial dilutions of pHu-E16 variants were incubated on
plates coated with WNV DIII and detected with a HRP-conjugated anti-human gamma chain antibody. Dilutions of pHu-E16 were used in parallel as
reference standards. A commercial generic human IgG (Southern Biotech) was used as a negative control. One set of representative O.D. 450 nm
readings from several independent experiments is presented. B. Binding of pHu-E16scFv-CH
1-3 to domain III of WNV E displayed on the cell surface of
yeast. Yeast cells displaying domain III of WNV E protein were stained with pHu-E16scFv-CH
1-3, mHu-E16 (positive control), or a plant-produced
humanized MAb against Ebola virus GP1 protein (negative control). Yeast cells were then processed by flow cytometry. Representative data from
three independent experiments are shown.
doi:10.1371/journal.pone.0093541.g005
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a phenomenon unique to plant cells, we compared the N-linked
glycan profiles of the equivalent Hu-E16 counterpart variants
produced in mammalian cells. Our results indicated that in
addition to the predominant complex-type glycans (GnGnF6 and
AGnF6), mHu-E16scFv-CH
1-3 also had a substantial amount of
oligomannosidic glycans, mostly M5 and M7, whereas no such
glycans were observed in the native IgG version of mHu-E16. This
result suggests that at least for Hu-E16, the unusual N-linked
glycosylation of scFv-CH
1-3 is not unique to plants but shared by
mammalian cells, even though the percentage and the particular
species of oligomannosidic glycans varies between the two cell
types.
To provide further insight for this N-glycosylation difference, we
expressed three additional pHu-E16 variants with various
combinations of HC and LC components. We were particularly
interested in examining whether LC or the proper pairing of HC
and LC impacted the N-linked glycosylation of MAb and its
variants. Co-expression of LC with pHu-E16scFv-CH
1-3 increased
its level of complex N-linked glycans percentage. In Tetra pHu-
E16, the co-expression and pairing of scFv-CL with scFv-CH
1-3
also increased the amount of complex-type N-linked glycans.
Furthermore, the pairing of the HC of pHu-E16 with scFv-CL
resulted in a predominantly complex-type N-linked glycosylation
pattern, similar to seen with the parent pHu-E16. These results
support the hypothesis that CL domain of an antibody is essential
for its secretion in the cell [36]. It was suggested previously that
HC dimers are retained in the ER by the chaperone BiP and are
released only upon binding with CL to ensure its proper folding
[37]. Our results corroborate this and highlight the importance of
LC pairing with HC for the proper processing of antibody N-
linked glycosylation. We speculate that in the absence of LC pHu-
E16scFv-CH
1-3 was retained in the ER by BiP, which prevented its
transport within the endomembrane system and resulted in the
observed ER-typical oligomannosidic glycoform. In contrast, co-
expression of LC or pHu-E16scFv-CL enabled the CL domain to
release pHu-E16scFv-CH
1-3 from BiP and to transport it to the
Golgi compartments for further assembly, glycan processing and
secretion. While the N-linked glycosylation of the scFv-CH
1-3 and
scFv-Fc variant may be regulated by many factors, our results
suggest that the lack of CL and its pairing with the CH
1 contributes
to the aberrant N-linked glycosylation and intracellular localiza-
tion of pHu-E16scFv-CH
1-3 and other previously reported scFv-
Fcs; the impact of this process may vary depending on the specific
scFv-Fc/scFv-CH
1-3 or the cell type in which it was produced.
We used wild-type (WT) N. benthamiana plants to express the
pHu-E16 variants. While N-linked glycosylation of proteins in
plants is similar to that of mammalian cells, WT plants add plant-
specific b-1,2-xylose and core a-1,3-fucose residues to complex N-
Figure 6. Neutralization of WNV by pHu-E16 variants. WNV was incubated with serial dilutions of mHu-E16 (positive control 1), or pHu-E16
(positive control 2), pHu-E16scFv-CH
1-3, or Tetra pHu-E16 and used to infect Vero cells. Cells were then fixed, permeabilized, analyzed by focus
reduction assay and quantitated by Biospot analysis. Mean 6 SEM is shown from one of several independent experiments. EC50 values are listed
below the graphs.
doi:10.1371/journal.pone.0093541.g006
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linked glycans and lack terminal b1,4-Gal and N-acetylneuraminic
acid (Neu5Ac) residues [38,39]. Differences in protein glycosyla-
tion between WT plant and mammalian cells remain a reservation
of plant-expression platforms for human therapies, because they
could produce glycoforms that alter efficacy or result in plant-
glycan specific immune responses that can accelerate protein
clearance or cause potential adverse effects through immune
complex formation. To overcome this challenge, glycosylation
pathway in N. benthamiana and several other plants has been
‘‘humanized’’ through glycoengineering, for example, by geneti-
cally suppressing or eliminating enzymes for the biosynthesis of
plant-specific glycans and by introducing glycoenzymes from
mammalian cells [39]. These efforts have lead to the creation of a
portfolio of ‘‘humanized’’ plant lines that produce MAbs that lack
plant-specific glycans and produce glycoforms that are essentially
mammalian [39]. For example, a double knockout (DXF) N.
benthamiana plant line suppresses the expression of a-1,3-fucosyl-
transferase and b-1,2-xylosyltransferase and was used for produc-
tion of an anti-Ebola MAb 13F6 [31,40]. 13F6 produced in the
DXF plant line had no plant-specific N-glycans and 90% of 13F6
had the predicted mammalian glycoform GnGn [31]. In contrast,
mammalian cell-produced 13F6 had a mixture of 3–5 glycoforms
with the most dominant glycoform (G0) ranging from 35–53%
[31]. The high glycan homogeneity of plant-made 13F6 and the
lack of core fucose increased its protection of mice against a lethal
Ebola virus challenge compared to the mammalian cell produced
13F6 [31]. We plan to express pHu-E16 scFv-CH
1-3, Tetra-E16,
and other variants in these ‘‘humanized’’ N. benthamiana lines to
produce highly uniform mammalian glycoforms.
The N-linked glycosylation pattern in the Fc region of an
antibody affects its binding to FccRs and C1q, and consequently
alters its effector function such as antibody-dependent cell
mediated cytotoxicity (ADCC) and complement-dependent cyto-
toxicity (CDC) [17]. The highly homogenous and defined nature
of N-glycans displayed by plant-derived MAbs provides the
opportunity to develop MAb glycoforms that enhance the efficacy
through modulating their effector function. For example, plant-
produced 13F6 has a higher affinity to FccRIII (CD16) than its
mammalian cell-produced counterpart, and provided better
protection against Ebola virus challenge in mice presumably via
enhanced ADCC activity [31]. Here, we found that due to their
distinct N-glycoforms, pHu-E16, pHu-E16scFv-CH
1-3, and Tetra
pHu-E16 exhibited differential binding to C1q and several FccRs
including CD16V158, CD16F158 CD32A-R131 and CD32A-H131,
CD32B, and CD64. For example, although pHu-E16 showed
reduced binding to all FccRs and C1q, pHu-E16scFv-CH
1-3
Figure 7. pHu-E16 variants mediated protection in mice. A. Five week-old C57BL/6 mice were passively transferred saline, 100 ng of mHu-E16,
or serial 10-fold increases in dose (ranging from 1 to 100 ng, n=10 mice per dose) of pHu-E16scFv-CH
1-3 via an intraperitoneal route on the same day
as subcutaneous infection with 102 PFU of WNV. Survival data was pooled from at least two independent experiments and analyzed by log-rank test.
B. Wild type C57BL/6 mice were infected with 102 PFU of WNV and then given a single 50 mg dose of pHu-E16 scFv-CH
1-3, Tetra pHu-E16 or mHu-E16
via an intraperitoneal route at day +4 after infection. Survival data was pooled from at least two independent experiments (n= 10 mice per dose) and
analyzed by the log-rank test.
doi:10.1371/journal.pone.0093541.g007
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demonstrated slightly enhanced binding to the low-affinity
(CD16F158) isoform of CD16A and CD64, and maintained similar
binding to the high-affinity (CD16V158) CD16A isoform as mHu-
E16. This diversity of binding affinity to C1q and various FccRs
by an individual MAb variant molecule will allow investigation of
the impact of glycan moieties on MAb effector function and the
development of MAb variants that are best suited for its efficacy or
safety depending on the particular clinical application.
In addition to ADCC and CDC, the interaction between Fc and
FccRs can have pathogenic consequences. For example, one of the
major impediments towards developing antibody-based therapeu-
tics for certain flavivirus infections (e.g., Dengue virus) is the at
least theoretical risk of ADE, which may render anti-flavivirus
MAb treated subjects more susceptible to infection. ADE occurs
because sub-neutralizing concentrations of antibodies (including
therapeutic MAbs) form complexes with the infecting flavivirus
that bind to FccR-bearing cells, resulting in increased virus uptake
and infection [19–21]. We investigated whether the unique
binding of pHu-E16 variants to FccRs affected ADE. Our results
demonstrated that all pHu-E16 variants lost ADE activity on
CD32A-expressing K562 cells. Thus, plant complex-type N-
glycans or the mammalian form of oligomannosidic glycans
carried by plant-produced pHu-E16 variants do not induce the
development of ADE efficiently on cells bearing CD32A,
consistent with their loss of binding in vitro as shown by SPR. In
a separate experiment, we observed that ADE also was eliminated
for a glycoengineered plant-derived pHu-E16 that carried the
mammalian glycoform of GnGn (data not shown). Collectively,
these results demonstrate the potential of plant-made MAbs and
their variants to be used as therapeutics against ADE-prone
viruses. Although it was previously reported that an aglycosylated
version of a MAb can eliminate the risk of ADE [41,42], the
complete removal of N-linked glycans and the resulting abolish-
ment of binding to C1q also may compromise the efficacy of a
MAb that uses CDC activity. Plant-derived MAb glycolvariants
that minimize ADE but retain C1q binding might have better
efficacy than their aglycosylated counterparts. While ADE is not a
critical issue for WNV infection, it is relevant to the closely related
Dengue virus, and some coronaviruses, paramyxoviruses, and
lentiviruses [43].
In summary, we established the ability of plant cells to express
and assemble a large and complex IgG-like tetravalent MAb
variant. The demonstration of in vitro and in vivo therapeutic
function of Tetra pHu-E16 also supports the feasibility of
developing bifunctional MAbs that can cross the BBB and extend
the window of treatment for WNV infection. This may lead to the
generation of better antibody-based therapeutics against WNV
and other neurological diseases. This study also highlights the
importance of HC and LC pairing for MAb N-glycan processing
and intracellular localization, which contributes to our under-
standing of this basic biological process in plant and animal cells.
Finally, our study suggests that structural difference between MAb
variants could impact N-linked glycosylation patterns, which in
turn can affect in vivo efficacy and safety.
Materials and Methods
Expression of pHu-E16 MAb variants in N. benthamiana
leaves
A plasmid containing the pHu-E16 MAb sequence [11] was
used as template for the construction of the pHu-E16scFv. Primers
H5 (59 GAATTCACAA TGGGATGG 39) and H3 (59
CCTCCTGAAG TTGAACCAGA AGACACAGTA ACAG-
TAG 39) were used to amplify the pHu-E16 VH, and primers
L5 (59 GGTTCAACTT CAGGAGGAGG ATCAGGTGGT
GGTTCAGGAG GTGGAGGATC TTCT GATATC GTTAT-
GACAC AATC 39) and L3 (59 TGCTAGCTT TGATCTCCAA
CTTAGTTCC 39) were used to amplify the pHu-E16 VL.
Subsequently, the VH and VL sequences were linked together by
overlapping PCR. The product was cloned using EcoRI and NheI
sites into a plasmid, which already contains the coding sequence of
the CH
1-3 or CL to yield EcoRI-pHu-E16scFv-CH
1-3-BamHI or
EcoRI-pHu-E16scFv-CL-BamHI constructs. pHu-E16scFv-CH
1-3
and E16scFv-CL coding sequences were then cloned into plant
expression vector pICH11599 and pICH21595, respectively with
EcoRI and BamHI restriction enzymes. The construction of pHu-
E16 HC and pHu-E16 LC in pICH11599 and pICH21595 has
been described previously [11]. None of the pHu-E16 constructs
contains the ER-retention signal KDEL. Plant expression vectors
were transformed individually into A. tumefaciens GV3101 by
electroporation as previously described [44]. Wild-type N.
benthamiana plants were grown and Agroinfiltrated or co-Agroinfil-
trated with GV3101 strains containing the pHu-E16scFv-CH
1-3,
pHu-E16scFv-CH
1-3/LC, HC/pHu-E16scFv-CL or pHu-
E16scFv-CH
1-3/ pHu-E16scFv-CL 39 modules along with their
respective 59 modules and an integrase construct as described
previously to express pHu-E16 variants [11,45]. To enhance the
assembly of pHu-E16scFv-CH
1-3/LC, HC/pHu-E16scFv-CL and
Tetra pHu-E16 molecules, the OD600 ratio of 4:1 for HC-derived
construct: LC-derived construct was used for Agrobacterium co-
infiltration.
Extraction and purification of pHu-E16 variants from
plant leaves
For evaluating the temporal pattern of pHu-E16 variant
expression, Agroinfiltrated leaves were harvested 5, 6, 7, 8, 9,
and 10 dpi. Leaves were harvested 9 dpi for other protein analysis.
Extraction and purification of pHu-E16 variants from plant leaves
were performed with a method previously reported for pHu-E16
MAb [11]. Briefly, leaves were homogenized in extraction buffer
(PBS, 1mM EDTA, 10 mg/ml sodium ascorbate, 10 mg/ml
leupeptin, and 0.3 mg/ml PMSF). The crude plant extract was
clarified by centrifugation at 17,7006g for 30 min at 4uC. pHu-
E16 variants in clarified protein extract were purified by a two-step
purification process comprised of ammonium sulfate precipitation
and protein A affinity chromatography.
SDS-PAGE, Western blot, ELISA and flow cytometry with
yeast surface display
Protein samples were subjected to 10% SDS-PAGE under
reducing (5% v/v b-mercaptoethanol) or to 4-20% gradient SDS-
PAGE under non-reducing conditions. Gels were stained with
Coomassie blue or used to transfer proteins onto PVDF
membranes. Horseradish peroxidase (HRP)-conjugated antibodies
against human-kappa LC or gamma HC (Southern Biotech) were
used for western blot analysis as previously described [11]. pHu-
E16 variant expression and antigen binding was examined with an
ELISA as described [11]. Briefly, DIII (amino acids 296-415) of
the New York 1999 strain of WNV purified from E. coli [46,47]
was immobilized on microtiter plates. After incubation with plant
protein extract or purified pHu-E16 variants, an HRP-conjugated
anti-human-gamma HC antibody (Southern Biotech) was used as
the detection antibody. The plates were developed with TMB
substrate (KPL Inc). mHu-E16 [25] and pHu-E16 [11] were used
as reference standards. Since this ELISA measured the quantity of
HC, it provided a molar equivalent of each pHu-E16 variant to
pHu-16 rather than their yield in mass. Thus, the yield (mg/g
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LFW) of each variant was calculated by the formula: (ELISA HC
equivalent value)/ (molecular weight of pHu-E16 (150 kDa)) X
(molecular weight of the variant) (125 kDa for the pHu-E16scFv-
CH
1-3, 170 kDa for pHu-E16scFv-CH
1-3/LC, 175 kDa for HC/
pHu-E16scFv-CL and 200 kDa for tetra pHu-E16). Yeast
displaying WNV DIII on their surface were generated, stained
with MAb variants, and analyzed with a Becton Dickinson
FACSCalibur flow cytometer as described [11,25].
N-linked glycan analysis
The N-linked glycosylation profile was determined by LC-ESI-
MS as previously published [48]. Briefly, purified MAb variants
were separated by reducing SDS-PAGE and detected with
Coomassie stain, and the HC-containing band was excised from
the gel. Upon S-alkylation and tryptic or tryptic/GluC digestion,
fragments were eluted from the gel with 50% acetonitrile and
separated on a Reversed Phase Column (15060.32 mm BioBasic-
18, Thermo Scientific) with a gradient of 1%–80% acetonitrile.
Glycopeptides were analyzed with a quadruple time-of-flight (Q-
TOF) Ultima Global mass spectrometer (Waters, Milford, MA,
USA). Spectra were summed and deconvoluted for identification
of glycoforms. Glycans were annotated according to the
ProGlycAn nomenclature (www.proglycan.com).
Surface plasmon resonance
Binding activity measurements of MAb variants for human C1q
and FccRs (CD16A-158va l (CD16V158), CD16A-158phe
(CD16F158) CD32A-131arg (CD32A-R131), CD32A-131his
(CD32A-H131), CD32B, and CD64) were performed by SPR on
a BIAcore 3000 biosensor (GE, Healthcare). WNV E protein was
immobilized on the CM-5 sensor chip (,3000 RU) by an amine
coupling kit as recommended by the manufacturer. Hu-E16
variants were bound to the E protein surface at approximately
700RU and normalized to the same level. The capture of Hu-E16
variants on the surface of immobilized antigen prevents the ligand
from deactivation and positions Fc regions of it in universal
orientation. This is followed by injection of C1q at 50 nmol/L or
the soluble monomeric receptors CD16A-158val, CD16A-158phe
at concentrations of 500 nmol/L, respectively, and flow rate of
30 ml/min for 60 sec with dissociation time 60 sec. Dimeric Fc-G2
(N297Q) fusions of human CD32B, CD32A-R131, and CD32A-
H131, or human soluble CD64 were injected at 200 nmol/L or at
50 nmol/L, respectively. Each receptor was injected in duplicate.
Between experiments, the naked antigen surface was regenerated
by pulse injection of 10 mM glycine pH 1.5. All binding
experiments were performed in 10 mM HEPES, pH 7.4,
150 mM NaCl, 3 mM EDTA, and 0.005% P20 surfactant.
Antibody-dependent Enhancement Assay
The enhancing activity of the MAbs was determined with
CD32A+ K562 cells [22] in at least three independent experiments
in triplicate using a high-throughput flow cytometry-based assay
with GFP pseudo-infectious WNV replicon particles essentially as
described [22]. K562 erythroleukemic cells were obtained from
the American Type Cell Collection (ATCC CCL-243).
WNV neutralization
A focus reduction neutralization assay was used to assess the
neutralizing activity of pHu-E16 variants against WNV essentially
as previously described [23]. Neutralization curves were generated
using Prism software to express the percent reduction of spot
numbers in samples pre-incubated with mAb compared to wells
with virus pre-incubated with medium alone, and EC50 values
calculated.
Efficacy of MAbs in vivo
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee at the Washington University School of Medicine
(Assurance Number: A3381-01). Injections were performed under
anesthesia that was induced and maintained with ketamine
hydrochloride and xylazine, and all efforts were made to minimize
suffering. C57BL/6 mice were housed in a pathogen-free mouse
facility. Mice received a single dose of purified pHu-E16scFv-CH
1-
3, Tetra pHu-E16, or mHu-E16 by intraperitoneal injection the
same day or four days after footpad infection with 102 PFU of
WNV strain 3000.0259. Kaplan-Meier analysis of survival data
was performed using the log-rank test. IC50 analyses were
performed by non-linear regression and statistical significances
were determined using analysis of variance (ANOVA) and F-tests.
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